Home Cart Sign in  
Chemical Structure| 1013101-36-4 Chemical Structure| 1013101-36-4

Structure of PF-04691502
CAS No.: 1013101-36-4

Chemical Structure| 1013101-36-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PF-04691502 is an ATP-competitive PI3K (α/β/δ/γ)/mTOR dual inhibitor with Ki of 1.8 nM/2.1 nM/1.6 nM/1.9 nM and 16 nM, little activity against either Vps34, AKT, PDK1, p70S6K, MEK, ERK, p38, or JNK.

Synonyms: PF4691502

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PF-04691502

CAS No. :1013101-36-4
Formula : C22H27N5O4
M.W : 425.48
SMILES Code : O=C1C(C2=CC=C(OC)N=C2)=CC3=C(C)N=C(N)N=C3N1[C@H]4CC[C@H](OCCO)CC4
Synonyms :
PF4691502
MDL No. :MFCD18782794

Safety of PF-04691502

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of PF-04691502

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • p110γ

    PI3Kγ, Ki:1.9 nM

  • p110β

    PI3Kβ, Ki:2.1 nM

  • p110α

    PI3Kα, Ki:1.8 nM

  • p110δ

    PI3Kδ, Ki:1.6 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
UM-SCC1 1.25 μM 6, 12, 24 hours PF-502 inhibited PI3K and TORC2 targets p-Akt (T308/S473), and enhanced TP53 and p73 expression. PMC3715575
UM-SCC46 1.25 μM 6, 12, 24 hours PF-502 inhibited PI3K and TORC2 targets p-Akt (T308/S473), and enhanced TP53 and p73 expression. PMC3715575
HUCCT1 0.5 µM 48 hours PF-04691502 inhibited the activation of the PI3K signaling pathway and reduced the expression of CCND1 PMC10053751
RBE 0.5 µM 48 hours PF-04691502 inhibited the activation of the PI3K signaling pathway and reduced the expression of CCND1 PMC10053751
OCI-My5 cells 0.1 µM 16 hours PF-04691502 reduced the phosphorylation of Akt at both Thr308 and Ser473, and decreased the phosphorylation of FoxO3a. PMC7226186
KMS-11 cells 0.1 µM 16 hours PF-04691502 reduced the phosphorylation levels of Akt and FoxO3a. PMC7226186
ORL-115 0.25 μM 24 hours significantly improved growth inhibition in ORL-115 cells PMC6713638

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice UM-SCC1 and UM-SCC46 xenograft models Oral gavage 25 mg/kg Once daily for 4 weeks PF-502 significantly inhibited tumor growth in UM-SCC1 and prolonged survival, but had a lesser effect on UM-SCC46 tumor growth and survival. PMC3715575
nude mice iCCA xenograft model oral 0.2 mg/kg/day Once daily for 7 or 28 days PF-04691502 monotherapy delayed tumor growth, but the combination with palbociclib showed more significant tumor growth inhibition PMC10053751
mice ORL-115 xenograft model oral 0.1 mg/kg Once daily for 2 weeks combination treatment resulted in the gradual decrease of tumor volumes PMC6713638

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00927823 Cancer PHASE1 COMPLETED 2025-04-12 Pfizer Investigational Site, L... More >>os Angeles, California, 90095-6984, United States|Pfizer Investigational Site, Los Angeles, California, 90095, United States|Pfizer Investigational Site, Los Angeles, California, 90404, United States|Pfizer Investigational Site, Santa Monica, California, 90404, United States|Pfizer Investigational Site, Detroit, Michigan, 48201, United States|Pfizer Investigational Site, Amherst, New York, 14221, United States|Pfizer Investigational Site, Buffalo, New York, 14263, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.35mL

0.47mL

0.24mL

11.75mL

2.35mL

1.18mL

23.50mL

4.70mL

2.35mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories